Login to Your Account

Regulus, AstraZeneca Deal Rekindles Interest in RNA

By Catherine Shaffer
Staff Writer

Thursday, August 16, 2012
Regulus Therapeutics Inc., of La Jolla, Calif., inked another two deals related to its microRNA technology. Its agreement with London's AstraZeneca plc calls for a $28 million up-front cash and equity payment, plus milestones, for development of three microRNA targets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription